Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Polycystic Ovarian Syndrome Therapeutics Market is Forecasts to Show Low Growth Until 2016 GlobalData estimated that the global polycystic ovarian syndrome market (PCOS) was valued at $706m in 2009 and forecasts it to shrink by 0.8% annually for the next seven years. The growth rate from 2001-09 was 6.8%. The patent of Letrozole will expire in the year 2011. As a result, the market will shrink by 30.1% and will come down to $562m in 2012. The market will start growing from 2013 due to the increase in disease prevalence and prescription rates and will rise to $702m in 2016. The CAGR from 2009-16 will be -0.8%. This slow growth rate is primarily due to the presence of a large number of generic drugs in the market and the absence of effective pipeline molecules. However, the treatment seeking and diagnosis rates will also boost the PCOS market to some extent. Hence, the overall PCOS market will have very slow growth in the upcoming years. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Polycystic-Ovarian-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Current Market Unsuccessful in Meeting Existing Market Need GlobalData found that the existing drugs are not serving the market sufficiently. The current competition in the PCOS market is weak and due to the fact that there are relatively few marketed products, there is a high level of unmet need. In 2009, the unmet need was approximately $233m. Although the currently marketed and off-label products possess high safety profiles, they lack significant efficacy profiles. This creates a huge unmet need in the market. Thus, there is huge market potential for new entrants that can take advantage of this scenario by introducing products that are more efficacious than the existing products. However, this need will continue to exist due to the absence of a strong pipeline. In order to serve this market successfully the companies need to treat this syndrome with products that are more efficacious and safer than the existing products.
Competition in the Polycystic Ovarian Syndrome Market Will Remain Moderate According to GlobalData, Sanofi Aventis, Bristol Myers Squibb, Novartis Pharmaceuticals, Sandoz Inc, Genpharm Inc, Ivax Pharmaceuticals Inc, Barr Laboratories Inc, Par Pharmaceuticals Inc and Genpharm Inc remain the leading companies in the global PCOS market. Together, these companies account for the majority of the PCOS market. However, Merck CoA is the only player likely to enter this market in the future. Due to the inactivity of companies in the clinical trial studies for PCOS, the competition will remain unchanged. The competition will mainly come from the generics present in the market. The present competition in the PCOS market is weak and is unlikely to intensify in the forthcoming years. To treat this syndrome, the treatment of the associated conditions like hyperglycemia, hyperandrogenism and anovulation is required. The currently active companies target the treatment of these associated conditions with their products. At present, the market is devoid of companies that can treat all of these conditions together. A company that markets a drug that can treat all of these conditions significantly will surely pose a competitive threat to all the other existing companies. Weak Pipeline Raises No Hope to Polycystic Ovarian Syndrome Treatment Paradigm GlobalData’s analysis shows that the products for polycystic ovarian syndrome in the pipeline are not strong enough to meet the existing market demand. The pipeline lacks the potential to produce blockbuster drugs and is devoid of significant support from pharmaceutical companies. There are only 18 molecules in the pipeline out of which only one drug is being developed by a pharmaceutical company. Trials for all the other products are sponsored by universities and research centers. Most of the pipeline products treat the hyperglycemia and hypercholesterolemia conditions associated with this syndrome. There are six first-in-class molecules with novel mechanisms of action to treat this syndrome. There are six combination drugs that include already used products in their trials. Thus, only a few new drugs will enter the market, alongside some combinations of existing marketed drugs for the PCOS market in the coming years.
Dominance of Generic Drugs Setting the Stage for a Price War While the prevailing market landscape remains dominated by generic drugs, the absence of a sufficient number of pipeline products reduces the number of branded products that will be introduced into the PCOS market. This will lead to continuation of the dominance of generics in this market. The presence of a large number of generic drugs will force the companies to pull down their drug prices. The companies will have to lower the prices of branded drugs prices in order to compete with low prices of generic drugs. This will lead to price war in the market where all the drugs will compete with each other on the basis of their low prices. As the annual cost of therapy for PCOS is low, the companies will not be encouraged to lower their prices further in order to compete with generics. This will trigger a scenario where all the existing players in the market will enter into price war thereby avoiding any further investment in finding molecules with novel mechanisms of action to treat this syndrome. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Polycystic-Ovarian-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Weak Pipeline Candidates Will Play No Role in Intensifying Future Competition GlobalData found that there are 18 molecules in different development stages in the pipeline of PCOS. Follitropin alpha liquid formulation, Simvastatin, Human Chorionic Gonadotropin, Dietary supplement Diamel are the key products in Phase III of PCOS pipeline. These late stage pipeline products show features such as HMG-CoA inhibitor, insulin secretion stimulator and female gamete enhancer. If successfully launched, these products are expected to meet physicians’ expectations. However, the fact that these molecules are developed by universities makes their launch skeptical. Due to this, the pipeline molecules may have no considerable impact on the competitive landscape for PCOS.
GlobalData, the industry analysis specialist, has released a new report, “Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global polycystic ovarian syndrome (PCOS) market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global PCOS sector. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Polycystic-Ovarian-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam email@example.com +914066166782